Abstract

Breast cancer is the most common cancer among females in Taiwan. Tamoxifen is an important adjuvant therapy for breast cancer. Although tamoxifen maculopathy has been reported in case series, typical central serous chorioretinopathy (CSCR) was reported only in one case. Here, we present a 67-year-old postmenopausal female with left triple-positive breast cancer who received an adjuvant low-dose tamoxifen regimen with 10 mg twice daily for 7 years. She developed presumed tamoxifen-related CSCR and was successfully treated by focal laser.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call